Patents by Inventor Emmanuel Y. Merigeon

Emmanuel Y. Merigeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11795193
    Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: October 24, 2023
    Assignee: Gliknik Inc.
    Inventors: David S. Block, Emmanuel Y. Mérigeon, Henrik Olsen
  • Publication number: 20220204552
    Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Application
    Filed: September 14, 2021
    Publication date: June 30, 2022
    Inventors: David S. BLOCK, Emmanuel Y. Merigeon, Henrik Olsen
  • Patent number: 11155574
    Abstract: The present disclosure involves optimized methods for production of hiologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 26, 2021
    Assignee: GLIKNIK INC.
    Inventors: David S. Block, Emmanuel Y. Mérigeon, Henrik Olsen
  • Publication number: 20200239518
    Abstract: The present disclosure involves optimized methods for production of hiologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Application
    Filed: December 8, 2017
    Publication date: July 30, 2020
    Inventors: David S. BLOCK, Emmanuel Y. MÉRIGEON, Henrik OLSEN